FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE
Peakfluorescein sodium and benoxinate hydrochloride
NDAOPHTHALMICSOLUTION/DROPS
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE (fluorescein sodium and benoxinate hydrochloride) by Bausch + Lomb is 12. First approved in 2020.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Fluorescein sodium and benoxinate hydrochloride is a fixed-dose ophthalmic solution combining a diagnostic dye and topical anesthetic for corneal procedures. It provides rapid corneal anesthesia (5-45 seconds) lasting approximately 20 minutes while enabling visualization through fluorescein's diagnostic properties. The combination is used in ophthalmology for diagnostic and minor surgical procedures requiring transient corneal numbing.
Peak11.5 years to LOE
Product is in peak commercial phase with stable market position; commercial team likely focused on market penetration and ophthalmology specialist engagement.
Mechanism of Action
12.2 Pharmacodynamics Maximal corneal anesthesia usually occurs in about 5-45 seconds and lasts about 20 minutes after single administration. The anesthetic effect may be extended by subsequent administration 10-20 minutes after the last administration.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on this product offers stability within a mature, specialty ophthalmic franchise at Bausch + Lomb with a clear competitive moat through 2037. Roles emphasize direct customer relationships with ophthalmologists and surgical centers rather than clinical development or major marketing innovation.
Brand Manager
Worked on FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.